| Autor: |
Deyan Davidov |
| Jazyk: |
angličtina |
| Rok vydání: |
2008 |
| Předmět: |
|
| Zdroj: |
Journal of IMAB, Vol 14, Iss 1, Pp 48-50 (2008) |
| Druh dokumentu: |
article |
| ISSN: |
1312-773X |
| DOI: |
10.5272/jimab.14-1-2010.48 |
| Popis: |
Background: Irinotecan is a topoisomerase I inhibitor that prolongs survival as second- line therapy in patients with metastatic colorectal cancer, treated with Fluorouracil and Leucovorin only. Aim: The aim of this study was to evaluate the efficacy and toxicity of the combination Irinotecan, Fluorouracil and Leucovorin. Methods: In the period 2006- 2007 34 patients with metastatic colorectal cancer entered the study. The treatment schedule consists of Irinotecan 180 mg/m2 day 1, Fluorouracil 400 mg/m2 day 1 and 2 and Leucovorin 200 mg/m2 day 1 and 2 every 14 days. Results: Overall response rate was 36,7% with three complete remissions. Median survival was 20,3 months. Diarrhea, vomiting and mucositis were most common side effects. Conclusions: That data suggest that the addition of Irinotecan to Fluorouracil and Leucovorin will offer opportunity to treat patients with metastatic colorectal cancer. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
